Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shai Shimony

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Leukemia|July 20, 2024
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomesJohann-Christoph Jann, Christopher B Hergott, Marisa Winkler, et al.
Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.
Blood Cancer Journal|November 1, 2024
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimenShai Shimony, Hari S Raman, Yael Flamand, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
American Journal of Hematology|May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort studyJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Haematologica|January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalitiesLeora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
American Journal of Hematology|October 6, 2025
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center StudyOren Pasvolsky, Shai Shimony, Rima M Saliba, et al.
Haematologica|March 17, 2022
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in childrenOded Gilad, Orly Dgany, Sharon Noy-Lotan, et al.
Blood Neoplasia|March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogeneticsLuis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Leukemia|July 20, 2024
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomesJohann-Christoph Jann, Christopher B Hergott, Marisa Winkler, et al.
Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.
Blood Cancer Journal|November 1, 2024
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimenShai Shimony, Hari S Raman, Yael Flamand, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
American Journal of Hematology|May 16, 2024
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort studyJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
Haematologica|January 29, 2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalitiesLeora Boussi, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
American Journal of Hematology|October 6, 2025
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center StudyOren Pasvolsky, Shai Shimony, Rima M Saliba, et al.
Haematologica|March 17, 2022
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in childrenOded Gilad, Orly Dgany, Sharon Noy-Lotan, et al.
Blood Neoplasia|March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogeneticsLuis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Pageof 8